<DOC>
	<DOCNO>NCT01337765</DOCNO>
	<brief_summary>This open label , dose finding , phase Ib clinical trial determine maximum tolerate dose ( MTD ) and/or RP2D orally administer PI3K/mTOR inhibitor BEZ235 combination MEK1/2 inhibitor MEK162 . This combination explore patient EGFR mutant NSCLC progress EGFR inhibitor triple negative breast cancer , well pancreatic cancer , colorectal cancer , malignant melanoma , NSCLC , advance solid tumor KRAS , NRAS , and/or BRAF mutation . Dose escalation guide Bayesian logistic regression model overdose control . At MTD RP2D , two expansion arm open order ass safety preliminary anti-tumor activity combination BEZ235 MEK162 . Study drug administer orally continuous schedule , MEK162 bid BEZ235 qd , treatment cycle define 28 day .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics BEZ235 Plus MEK162 Selected Advanced Solid Tumor Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histologically/cytologically confirm , advance non resectable solid tumor Measurable nonmeasurable , evaluable disease determine RECIST 1.0 Patients primary CNS tumor CNS tumor involvement Diabetes mellitus Unacceptable ocular/retinal condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>BEZ235 ,</keyword>
	<keyword>MEK162</keyword>
	<keyword>RAS RAF mutation ,</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>pancreatic cancer ,</keyword>
	<keyword>NSCLC progress EGFR TKI</keyword>
	<keyword>PI3K/mTOR inhibitor ,</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>Advanced select solid tumor</keyword>
</DOC>